1192722-01-2

Upstream product

• 331810-13-0 31,42-bis(trimethylsilylether)rapamycin 
• 598-21-0 2-Bromoacetyl bromide 
• 331810-10-7 31-(trimethylsilylether)rapamycin 
• 53123-88-9 sirolimus 

Downstream Products

• 1192722-03-4 42-O-[((R)-3-hydroxypyrrolidin-1-yl)acetyl]-31-O-trimethylsilyl-rapamycin 
• 851077-42-4 azidoacetic acid rapamycin ester 
• 1192721-52-0 42-O-[((R)-3-hydroxypyrrolidin-1-yl)acetyl]-rapamycin 

Relevant academic research and scientific papers

Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used as Potential mTOR-Targeted Anticancer Agents

Rapamycin, a potent antifungal antibiotic, was approved as immunosuppressant, and lately its derivatives have been developed into mTOR targeting anticancer drugs. Structure modification was performed at the C-42 position of rapamycin, and a novel series of rapamycin triazole hybrids (4a-d, 5a-e, 8a-e, and 9a-e) was facilely synthesized via Huisgen's reaction. The anticancer activity of these compounds was evaluated against the Caski, H1299, MGC-803, and H460 human cancer cell lines. Some of the derivatives (8a-e, 9a-e) appeared to have stronger activity than that of rapamycin; however, 4a-d and 5a-e failed to show potential anticancer activity. Compound 9e with a (2,4-dichlorophenylamino)methyl moiety on the triazole ring was the most active anticancer compound, which showed IC50 values of 6.05 (Caski), 7.89 (H1299), 25.88 (MGC-803), and 8.60 μM (H460). In addition, research on the mechanism showed that 9e was able to cause cell morphological changes and to induce apoptosis in the Caski cell line. Most importantly, 9e can decrease the phosphorylation of mTOR and of its downstream key proteins, S6 and P70S6K1, indicating that 9e can effectively inhibit the mTOR signaling pathway. Thus, it may have the potential to become a new mTOR inhibitor against various cancers. Novel rapamycin triazole hybrids were synthesized via Huisgen's reaction and their anticancer activities were evaluated against four human cancer cell lines. Compound 9e with a (2,4-dichlorophenylamino)methyl moiety on the triazole ring showed the highest anticancer activity (IC50 = 6.05-25.88 μM). Since 9e can also inhibit the mTOR signaling pathway, it may become a new mTOR inhibitor against various cancers.

Rapamycin derivative, preparation method, pharmaceutical composition and uses thereof

The present invention belongs to the field of medicine and chemical industry, and relates to a rapamycin derivative represented by a formula I, a preparation method, a pharmaceutical composition and uses thereof. According to the compound of the present i

Selective substitution of 31/42-OH in rapamycin guided by an in situ ir technique

An in situ IR technique was applied in the selective synthesis of the key intermediate for rapamycin derivatives, which made the reaction endpoint easily defined. This technology solved a bothersome problem in the preparation of rapamycin derivatives, and

RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS

Analogs and derivatives of rapamycin are provided, wherein the analogs and derivatives can bind to FK-506 binding protein (FKBP), or inhibit the mTOR function of an FKBP, or both. The analogs and derivatives are rapamycin include the rapamycin skeleton su